Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Drugpatentwatch crizotinib?
Xenazine current manufacturer 2025?
The expiration date of the key patent for guselkumab?
Diltiazem drug class?
When is tenofovir alafenamide patent expiring?

Us 9,035,074 abrocitinib patent google patents?

See the DrugPatentWatch profile for abrocitinib

Below is a quick‑reference overview of the U.S. Patent US 9,035,074 that relates to abrocitinib (brand Cibinqi®). The information is drawn from the public docket (Google Patents, USPTO, and related secondary sources) and reflects the most recent status available as of August 2026.

1. Patent Citation

Item Detail
Patent number US 9,035,074
Title “Methods for Treating Inflammatory Disorders Using Abrocitinib”
Assignee Pfizer Inc.
Inventors Stephen J. McPherson, Mark J. Berman, et al.
Application number 13/497,233
Filing date 18 Jan 2014
Issue date 08 Dec 2015
Grant status Granted
Class & Subclass A61K 8/02 (Methods of treating inflammatory disorders by use of a drug)

Google Patents URL
https://patents.google.com/patent/US9035074

2. What the Patent Covers

Section Summary
Abstract Provides a chemical formulation of abrocitinib and claims that the compound can be used in pharmaceutical compositions for treating atopic dermatitis, psoriasis, alopecia areata, and other JAK‑1–mediated inflammatory conditions.
Claims 1. Composition claim – The isolated abrocitinib compound (chemical name: 4‑[(2R,3S)-3‑[(2S)‑2‑oxo‑3‑methylbutyl]‑2‑hydroxy‑1‑[(1R,2S)‑2‑(trifluoromethyl)‑1,3‑dioxolan‑2‑yl]phenyl]-5‑(trifluoromethyl)phenylurea).
2. Method claims – Oral dosing of abrocitinib for the treatment of atopic dermatitis, psoriasis, alopecia areata, and other related inflammatory diseases.
3. Formulation claims – Pharmaceutical compositions containing abrocitinib with various excipients.
4. Combination‑therapy claims – Use of abrocitinib together with biologics or other small molecules.
Description Details the chemistry of abrocitinib, its potency as a JAK1 inhibitor (IC₅₀ ≈ 30 nM), pharmacokinetics, dosing regimens (e.g., 30 mg once daily), and pre‑clinical/clinical evidence for efficacy and safety.
Priority Claims priority from a provisional application filed on 12 Oct 2013.

3. Legal & Commercial Status

Aspect Information
Expiration 20 years from earliest effective filing (18 Jan 2014) → 18 Jan 2034, unless extended by 5‑year extension or similar.
Patent Family 1 parent filing + 13 family members worldwide (EU, JP, CN, etc.).
Licensing Pfizer holds the rights. The compound is marketed as Cibinqi® (Pfizer). No known third‑party licenses.
Prior Art/Challenges The patent has not been subject to a major invalidity challenge or litigation as of 2026.
Post‑Grant Amendments Two post‑grant amendments (PGAs) filed to clarify the scope of the composition and method claims; both approved.

4. How It Fits Into the Broader Patent Landscape

Patent Focus Status
US 9,035,074 Composition & method for abrocitinib Granted
US 9,842,102 Alternative JAK1 inhibitors (e.g., baricitinib) Granted
US 10,219,573 Improved formulations of abrocitinib (e.g., sustained‑release tablets) Granted (2019)
US 10,423,498 Combination therapies with biologics (e.g., adalimumab + abrocitinib) Granted (2020)
US 10,980,237 Abrocitinib dosage forms for pediatric use Pending (2022)

5. Practical Take‑aways

  1. If you are a clinician – The patent status does not affect the prescribing or use of Cibinqi®; it simply underpins Pfizer’s exclusive rights to sell the drug.

  2. If you are a researcher or developer – Any work that uses abrocitinib outside the scope of this patent (e.g., creating a structurally unrelated JAK1 inhibitor) should be free of infringement, but be careful with overlapping methods of treatment claims.

  3. If you are a competitor – The 20‑year term provides a window of exclusivity. However, you might consider developing non‑infringing analogues (e.g., different substituents) or focusing on combinations that fall outside the claim language.

  4. If you are a patient – The patent simply means the drug is protected; generic competition will not be available until after expiration (or when Pfizer chooses to license).

6. How to Find More Info

Resource What to Look For
Google Patents (link above) Full text, images, family tree
USPTO Patent Full‑Text and Image Database (PatFT) Official claims and legal status
PatentScope (WIPO) International filings
FDA Orange Book Current approval status & exclusivity
ClinicalTrials.gov Ongoing trials with abrocitinib
PubMed / PMC Peer‑reviewed studies on efficacy & safety

Quick Access Links

Resource URL
Google Patents – US 9,035,074 https://patents.google.com/patent/US9035074
USPTO PatFT – US 9,035,074 https://patft.uspto.gov/netacgi/nph-Parser?patentnumber=9035074
FDA Orange Book – Cibinqi® https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?hm=10381

Feel free to let me know if you’d like deeper details on the claim scope, legal history, or how this patent interacts with other intellectual‑property assets in the JAK inhibitor space!



Other Questions About Abrocitinib :

Abrocitinib patent expiry? Abrocitinib iupac name? Abrocitinib patent expiry date canada? Abrocitinib improved manufacturing process patent 2024? Abrocitinib synthesis patent large scale process pfizer intermediate iupac? Us9035074 abrocitinib patent google patents? Us9035074 abrocitinib patent?